Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Various Advanced Cancer × daratumumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 23 Recurrence 6 Neoplasms 4 Neoplasms, Plasma Cell 3 Lymphoma, Non-Hodgkin 3 Leukemia, Myeloid, Acute 3 Immunoglobulin Light-chain Amyloidosis 3 Hematologic Neoplasms 3 Paraproteinemias 2 Hematologic Diseases 2 Corneal Diseases 2 Carcinoma, Non-Small-Cell Lung 2 Blood Protein Disorders 2 Various Advanced Cancer 1 Triple Negative Breast Neoplasms 1 Proteostasis Deficiencies 1 Pancreatic Neoplasms 1 Neoplasm, Residual 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, Large B-Cell, Diffuse 1 Hodgkin Disease 1 Glioblastoma 1 Amyloidosis 1

Interventions

relatlimab 1 daratumumab 1 Nivolumab 1 Ipilimumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02488759 2023-11-13

CheckMate358

Bristol-Myers Squibb

Phase 1/2 Completed

578 enrolled 19 charts

Various Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡